Pneumatic Nebulizers Market Size, Share & Trends Analysis Report By Indication (Breath-actuated, Vented), By End-use (Hospitals & Clinics, Home Healthcare), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global pneumatic nebulizers market size was valued at USD 717.85 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.3% from 2023 to 2030. The increasing incidence of chronic respiratory diseases, demand for home healthcare devices, and growing geriatric population are expected to drive the market. For instance, according to the Global Burden of Disease Study, the occurrence of Chronic Pulmonary Respiratory Diseases (COPD) reached around 251 million. More than 90% of deaths were due to COPD, especially in low and middle-income countries. According to statistics published by the CDC, approximately 18.4 million adults in the U.S. have asthma. For instance, according to the World Health Organization, there are around 340 million people in the world suffering from asthma, and more than 80% of these belong to low and middle-income countries. 

The COVID-19 pandemic has impacted all industries, including the pneumatic nebulizer market. Asthma or COPD patients, aware of the risk of airborne transmission of COVID-19, were hesitant about using inhaled medications, which are considered potential sources of viral transmission and immunosuppression. However, medical practitioners advised all such patients to continue using their prescribed inhaled medications, including nebulizers. Therefore, the overall impact of COVID-19 on the market was minimal.

The easy availability of compact pneumatic nebulizers ideal for home use, and technological innovations in these devices to reduce the sound created by them & improve their functionality, are increasing their adoption in-home healthcare. For instance, in September 2021, Teva announced the launch of its two digital inhalers, “AirDuo Digihaler” and “AirmonAir Digihaler,” an inhalation powder. These digital inhalers help control asthma symptoms and prevent wheezing in people aged 12 and above. Moreover, these devices are favored by third-party payers, such as insurance companies, as they aim to reduce costs while providing quality healthcare services. These factors are expected to boost the adoption over the forecast period.

Indication Insights

The breath-actuated product segment held the largest revenue share of over 64.2% in 2022. The breath-actuated nebulizers elucidate higher drug delivery capacity and lesser dosage wastage features. Thus, the segment delivering advanced inhalation therapy is expected to dominate the market over the forecast period. For instance, in January 2023, the Food and Drug Administration (FDA) provided clearance to AstraZeneca Plc for releasing its Airsupra inhaler in the U.S. This inhaler helps treat and prevent bronchoconstriction. Also, it is the first metered-dose inhaler that has a specific combination of doses.

The vented segment is likely to grow at the fastest CAGR of 6.6% during the forecast period. Key players are focusing on developing innovative products. For instance, Ventec Life Systems received (510(k) clearance) U.S. FDA approval for VOCSN in April 2017. The device is a portable life support system that delivers five respiratory therapies, including nebulization, oxygen, cough, suction, and ventilation. In July 2020, OMRON Healthcare launched its OMRON NE C106, a compressor nebulizer. It turns compressor medications into a mist and helps them reach the patient’s lungs and provide instant relief from congestion and breathing ailments.

End-use Insights

The hospitals & clinics segment dominated the market in 2022, accounting for a revenue share of more than 65%. Hospitals are an integral part of the healthcare sector and a major revenue source for the entire industry. Therefore, multiple companies invest substantial efforts, both in terms of marketing strategies and revenue, to endorse their product/services among hospitals. In February 2018, Teva Pharmaceuticals launched its QVAR RediHaler, an innovative breath-actuated technology available to patients only by prescription. It was the first and only breath-actuated inhaler that provides the maintenance treatment of asthma patients aged four and above.

The home healthcare segment is likely to grow at the fastest CAGR of 6.7% during the forecast period. Over the recent years, home healthcare devices have been gaining popularity, driving segment growth. The easy availability of compact nebulizers ideal for home use and technological innovations to improve functionality are also increasing their adoption of in-home healthcare. Moreover, the rising geriatric population and the need to curb healthcare expenditure are anticipated to boost the adoption of home healthcare devices. The production and launch of various capsules and dry inhalers are also felicitating patients for home healthcare. For instance, In September 2022, Beximco Pharmaceuticals announced the launch of its ONRIVA TRIO BEXICAP, a dry inhaler capsule. This content included in the capsule helps to control asthma symptoms in ways such as, by helping the lungs muscles airways to stay relaxed to prevent bronchoconstriction and helping to reduce inflammation.

Regional Insights

North America accounted for the largest revenue share of more than 35.54% in 2022. According to the American Lung Association (ALA), around 24 million American adults may suffer from COPD. Moreover, the rise in the geriatric population in the U.S. is leading to a corresponding growth in the number of surgeries in the country, further boosting regional market growth. In December 2020, the U.S. FDA approved the connected nebulizer launched by AirHealth. It is a portable and electronic vibrating mesh device that helps to nebulize liquid medications for inhalation by patients anywhere.

Asia Pacific is expected to be the fastest-growing region, with a CAGR of 7.4% over the forecast period. The burden of COPD in Asia is greater than that in developed Western countries. In Japan, 90% of COPD patients reported a strong smoking history. A significant rise in the geriatric population in Japan is driving the product demand in the country, thereby supporting regional growth. For instance, in March 2021, PARI Pharma GmbH announced the approval for the LAMIRA Nebulizer System to deliver ARIKAYCE, an Insmed drug product in Japan.

Moreover, countries such as India and China are also predicted to have a significant population suffering from pulmonary diseases. The introduction of new facilities in healthcare products in India is also driving the segment's growth. For instance, in February 2023, Berry Global Group announced the establishment of a new manufacturing facility and healthcare center in Bangalore, India called “Silicon Valley,” to improve global access to healthcare products and the company’s R&D solutions. This R&D center has announced the launch of various healthcare products in 2023, such as Dry Powder Inhalers (DPI), plastic caps, and closures.

Key Companies & Market Share Insights

The global market is fairly competitive. The most notable participants in the market are Koninklijke Philips N.V. and OMRON Corporation. Key players are involved in new product launches, acquisitions, and partnerships to gain a competitive edge over each other. According to the article published in October 2022 by News Today, AeroRx Therapeutics is likely to collaborate with HCmed Innovations to discover a new therapeutic combination of different classes of medications (bronchodilators) that helps in opening the airways to ease breathing to treat the patient with chronic pulmonary disease (COPD). In January 2020, OMRON Corporation announced the opening of the Automation Center Tokyo (ATC-TOKYO) in Tokyo. With this center, customers can join the company to find solutions for any challenges arising during production. Some of the prominent players in the global pneumatic nebulizers market include:

• Koninklijke Philips N.V.

• OMRON Corporation

• PARI GmbH

• General Electric

• Allied Healthcare Products, Inc.

• BD (Becton, Dickinson & Company)

• GF Health Products, Inc.

• Medline Industries, LP

• Briggs Healthcare

• Vectura Group Ltd

Pneumatic Nebulizers Market Report Scope

Global Pneumatic Nebulizers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global pneumatic nebulizers market report based on indication, end-use, and region:

• Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Breath-actuated

  • Vented

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals & Clinics

  • Home Healthcare

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait